149 related articles for article (PubMed ID: 35595928)
21. Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.
Wong SM; Stout NK; Punglia RS; Prakash I; Sagara Y; Golshan M
Cancer; 2017 Jul; 123(14):2609-2617. PubMed ID: 28221673
[TBL] [Abstract][Full Text] [Related]
22. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
23. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
Jolly S; Kestin LL; Goldstein NS; Vicini FA
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
[TBL] [Abstract][Full Text] [Related]
24. Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade.
Lee J; Ku GY; Lee H; Park HS; Ku JS; Kim JY; Park S; Park BW
Cancer Res Treat; 2022 Oct; 54(4):1074-1080. PubMed ID: 34942684
[TBL] [Abstract][Full Text] [Related]
25. Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status.
Mao K; Yang Y; Wu W; Liang S; Deng H; Liu J
PLoS One; 2017; 12(5):e0176417. PubMed ID: 28467490
[TBL] [Abstract][Full Text] [Related]
26. Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience.
Hoffman DI; Zhang PJ; Tchou J
Surg Oncol; 2019 Mar; 28():190-194. PubMed ID: 30851899
[TBL] [Abstract][Full Text] [Related]
27. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
[TBL] [Abstract][Full Text] [Related]
28. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
Aulmann S; Penzel R; Schirmacher P; Sinn HP
Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
[TBL] [Abstract][Full Text] [Related]
29. Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary?
Sadek BT; Shenouda MN; Abi Raad RF; Niemierko A; Keruakous AR; Goldberg SI; Taghian AG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):726-30. PubMed ID: 24064317
[TBL] [Abstract][Full Text] [Related]
30. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.
Chuba PJ; Hamre MR; Yap J; Severson RK; Lucas D; Shamsa F; Aref A
J Clin Oncol; 2005 Aug; 23(24):5534-41. PubMed ID: 16110014
[TBL] [Abstract][Full Text] [Related]
31. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy.
Berg WA; Mrose HE; Ioffe OB
Radiology; 2001 Feb; 218(2):503-9. PubMed ID: 11161169
[TBL] [Abstract][Full Text] [Related]
32. The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS.
Brogi E
Virchows Arch; 2022 Dec; 481(6):823-837. PubMed ID: 35567633
[TBL] [Abstract][Full Text] [Related]
33. Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.
Nakhlis F; Katlin FD; Grossmith SC; DiPasquale A; Harrison BT; Schnitt SJ; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7696-7702. PubMed ID: 35771367
[TBL] [Abstract][Full Text] [Related]
34. Changing incidence of lobular carcinoma in situ of the breast.
Li CI; Anderson BO; Daling JR; Moe RE
Breast Cancer Res Treat; 2002 Oct; 75(3):259-68. PubMed ID: 12353815
[TBL] [Abstract][Full Text] [Related]
35. Core Breast Biopsies Showing Lobular Carcinoma In Situ Should Be Excised and Surveillance Is Reasonable for Atypical Lobular Hyperplasia.
Sen LQ; Berg WA; Hooley RJ; Carter GJ; Desouki MM; Sumkin JH
AJR Am J Roentgenol; 2016 Nov; 207(5):1132-1145. PubMed ID: 27532153
[TBL] [Abstract][Full Text] [Related]
36. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
37. Lobular carcinoma in situ (LCIS): pathology and treatment.
Gump FE
J Cell Biochem Suppl; 1993; 17G():53-8. PubMed ID: 8007710
[TBL] [Abstract][Full Text] [Related]
38. Clonal relationships between lobular carcinoma in situ and other breast malignancies.
Begg CB; Ostrovnaya I; Carniello JV; Sakr RA; Giri D; Towers R; Schizas M; De Brot M; Andrade VP; Mauguen A; Seshan VE; King TA
Breast Cancer Res; 2016 Jun; 18(1):66. PubMed ID: 27334989
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Goldstein NS; Kestin LL; Vicini FA
Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for routine screening MRI in women with LCIS?
King TA; Muhsen S; Patil S; Koslow S; Oskar S; Park A; Morrogh M; Sakr RA; Morrow M
Breast Cancer Res Treat; 2013 Nov; 142(2):445-53. PubMed ID: 24141896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
